Spotlight
Specialty
Partners
CME/CE
First-Line Options for Advanced/Metastatic Disease
A focused discussion on the available first-line treatment options for advanced/metastatic ESCC.
EP: 1.Trends in ESCC Incidence and Observations from Clinical Practice
EP: 2.Approaches to Biomarker Testing for ESCC
EP: 3.The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
Now Viewing
EP: 4.First-Line Options for Advanced/Metastatic Disease
EP: 5.Insights on ESCC First-Line Treatment Selection
EP: 6.RATIONALE-306 Data on Tislelizumab in ESCC
EP: 7.The Potential Impact of Tislelizumab on First-Line ESCC Treatment
EP: 8.Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
EP: 9.A Look Towards the Future of ESCC
Related Videos
